Genmab says J&J not exercising option on HexaBody-CD38
Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy,
Truist analyst Asthika Goonewardene lowered the firm’s price target on Genmab (GMAB) to $45 from $50 but keeps a Buy rating on the shares.
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other best ...
Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...
In trading on Friday, shares of Genmab A/S (Symbol: GMAB) crossed above their 200 day moving average of $24.14, changing hands as high as $24.32 per share. Genmab A/S shares are currently trading ...
In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed ...
Genmab (GMAB) reported strong Q4 2024 results last week and provided 2025 revenue guidance that was slightly ahead of the Street consensus and expense guidance that was below expectations.
We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...
In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other stocks. While stocks initially fell based on worries regarding Trump tariffs on America’s ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback